PFM
NVO

Potomac Fund Management’s Novo Nordisk NVO Stock Holding History

Potomac Fund Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,510
Closed -$1.65M – 112
2025
Q4 		$1.65M Buy
32,510
+13,033
+67% +$666K 0.06% 39
2025
Q3 		$1.08M Buy
19,477
+1,268
+7% +$74.2K 0.05% 51
2025
Q2 		$1.22M Buy
18,209
+1,393
+8% +$94.8K 0.07% 48
2025
Q1 		$981K Buy
16,816
+2,456
+17% +$203K 0.43% 33
2024
Q4 		$1.24M Buy
+14,360
New +$1.55M 0.07% 41

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Potomac Fund Management's NVO Position: Q1 2026 in Review

Potomac Fund Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 32,510 shares — an estimated $1.65M sold.

Potomac Fund Management first reported a position in NVO in Q4 2024 and held it in 5 quarters. The position peaked at $1.65M in Q4 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Potomac Fund Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Potomac Fund Management sold 32,510 Novo Nordisk shares in Q1 2026, an estimated $1.65M.
  • Potomac Fund Management first reported a position in Novo Nordisk in Q4 2024 and held it in 5 quarters.
  • Potomac Fund Management's Novo Nordisk position peaked at $1.65M in Q4 2025.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Potomac Fund Management's 13F filing for Q1 2026, filed 14 May 2026.